Robert C Kane

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy
    Robert C Kane
    Division of Drug Oncology Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland 20993 0004, USA
    Clin Cancer Res 12:2955-60. 2006
  2. ncbi Sorafenib for the treatment of advanced renal cell carcinoma
    Robert C Kane
    Division of Drug Oncology Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland 20993 0004, USA
    Clin Cancer Res 12:7271-8. 2006
  3. ncbi Bortezomib for the treatment of mantle cell lymphoma
    Robert C Kane
    Division of Drug Oncology Products, Office of Oncology Drug Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland 20993 0002, USA
    Clin Cancer Res 13:5291-4. 2007
  4. ncbi Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy
    Robert C Kane
    Office of Oncology Drug Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, 10903 New Hampshire Ave, Bldg 22, Room 2109, Silver Spring, Maryland 20993 0002, USA
    Oncologist 13:445-50. 2008
  5. ncbi The clinical significance of statistical significance
    Robert C Kane
    Office of Oncology Drug Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland 20993 0002, USA
    Oncologist 13:1129-33. 2008
  6. ncbi Sorafenib for the treatment of unresectable hepatocellular carcinoma
    Robert C Kane
    Office of Oncology Drug Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993 0004, USA
    Oncologist 14:95-100. 2009
  7. ncbi Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy
    Robert C Kane
    Division of Oncology Drug Products, Center for Drug Evaluation and Research, United States Food and Drug Administration, Rockville, Maryland, USA
    Oncologist 8:508-13. 2003

Detail Information

Publications7

  1. ncbi United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy
    Robert C Kane
    Division of Drug Oncology Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland 20993 0004, USA
    Clin Cancer Res 12:2955-60. 2006
    ..The FDA analysis of the trial data and bortezomib's regulatory development are summarized here...
  2. ncbi Sorafenib for the treatment of advanced renal cell carcinoma
    Robert C Kane
    Division of Drug Oncology Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland 20993 0004, USA
    Clin Cancer Res 12:7271-8. 2006
    ..S. Food and Drug Administration (FDA) review and approval of sorafenib (Nexavar, BAY43-9006), a new small-molecule, oral, multi-kinase inhibitor for the treatment of patients with advanced renal cell carcinoma (RCC)...
  3. ncbi Bortezomib for the treatment of mantle cell lymphoma
    Robert C Kane
    Division of Drug Oncology Products, Office of Oncology Drug Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland 20993 0002, USA
    Clin Cancer Res 13:5291-4. 2007
    ..To describe the Food and Drug Administration review and marketing approval considerations for bortezomib (Velcade) for the treatment of patients with mantle cell lymphoma...
  4. ncbi Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy
    Robert C Kane
    Office of Oncology Drug Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, 10903 New Hampshire Ave, Bldg 22, Room 2109, Silver Spring, Maryland 20993 0002, USA
    Oncologist 13:445-50. 2008
    ..For this uncommon but serious complication of anthracycline therapy, the need for surgical intervention was 1.7% with this regimen...
  5. ncbi The clinical significance of statistical significance
    Robert C Kane
    Office of Oncology Drug Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland 20993 0002, USA
    Oncologist 13:1129-33. 2008
    ....
  6. ncbi Sorafenib for the treatment of unresectable hepatocellular carcinoma
    Robert C Kane
    Office of Oncology Drug Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993 0004, USA
    Oncologist 14:95-100. 2009
    ..Montville, NJ, and Onyx Pharmaceuticals Corp., Emeryville, CA), an oral kinase inhibitor, for the treatment of patients with unresectable hepatocellular carcinoma (HCC)...
  7. ncbi Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy
    Robert C Kane
    Division of Oncology Drug Products, Center for Drug Evaluation and Research, United States Food and Drug Administration, Rockville, Maryland, USA
    Oncologist 8:508-13. 2003
    ..This report highlights the FDA analysis supporting the accelerated approval...